🇺🇸 FDA

Company profile · Sponsor

Editas

Editas Medicine

EDIT · NYSE biotech CAMBRIDGE, MA, USA
Pipeline
3
Drugs
0
Patents
8

Quick answer

Editas (EDIT) is a biotech company. headquartered in CAMBRIDGE, MA, USA. listed on NYSE. NovaPharmaNews links 3 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker EDIT
Exchange NYSE
Company type biotech
Headquarters CAMBRIDGE, MA, USA
SEC CIK 0001650664

Pipeline (3)

Search pipeline →

  1. EDIT-101

    Editas

    Leber Congenital Amaurosis 10

    phase 2 small molecule active

    1 trial

  2. EDIT-301

    Editas

    Sickle Cell Disease

    phase 2 gene therapy active

    1 trial

  3. EDIT-301

    Editas

    Transfusion Dependent Beta Thalassemia

    phase 2 gene therapy active

    1 trial

Patents (8)

Search patents →

  1. US 12359223

    Systems and methods for modulating chromosomal rearrangements

    Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12331328

    CRISPR/Cas9-mediated exon-skipping approach for USH2A-associated usher syndrome

    Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12325854

    Crispr-CPF1-related methods, compositions and components for cancer immunotherapy

    Expires Mon Jun 05 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12201699

    Compositions and methods for promoting homology directed repair

    Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12031132

    Systems and methods for the treatment of hemoglobinopathies

    Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11963982

    CRISPR/RNA-guided nuclease systems and methods

    Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11952408

    HPV-specific binding molecules

    Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11911415

    CRISPR/Cas-related methods and compositions for improving transplantation

    Expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Editas?

Editas (EDIT) is a biotech company. headquartered in CAMBRIDGE, MA, USA. listed on NYSE. NovaPharmaNews links 3 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does Editas sponsor?

We track 3 ClinicalTrials.gov-linked programs for Editas, including EDIT-101 and 2 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Editas company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.